BRAF and cancer: MEK inhibitors selectively inhibit mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) activity in individuals with v-raf murine sarcoma viral oncogene homolog B1 (BRAF) or RAS-positive malignancies or NF1, and impair signal transduction pathways that regulate proliferation and survival in cancer cells (Kuske et al., 2018; Klesse et al., 2020).